Latest news with #PeterSchwarz
Time Business News
23-07-2025
- Health
- Time Business News
Emerging Frontiers in Non-Insulin Treatments for Diabetes Mellitus
Non-insulin remedies for diabetes include drugs and treatments that help control blood sugar levels without using insulin, such as GLP -1 receptor agonist, SGLT 2 inhibitors, DPP -4 inhibitors, and lifestyle or device -based intervention. The market for these remedies is increasing due to the spread of growing global diabetes, an increase in demand for easy-to-use and low aggressive remedies, innovation in oral and injectable drug formulations, and weight loss compared to insulin, heart safety and better patients such as their additional benefits. Key Growth Drivers and Opportunities Rising Global Prevalence of Diabetes: The increasing global proliferation of diabetes, sedentary lifestyle, unhealthy diet and aging population are promoting considerable demand for effective and convenient treatment options. As more patients are diagnosed especially with type 2 diabetes there is a growing requirement of treatments managing blood sugar without complications of insulin use. Non-insulin therapy provides benefits such as weight loss and heart safety, such as oral administration, low side effects, and additional health benefits, making them a favorite option and accelerates their market growth. Challenges Non-insulin therapy for diabetes market faces many challenges, including high treatment costs, limited access to low and medium-income countries, and concerns on long-term security and side effects of new drug classes. Additionally, the patient may be affected by complex doses regimens or gastrointestinal side effects, and competition from insulin-based treatments remains stronger in some segments. Regulatory barriers and extensive clinical trials also slow down the introduction of innovative remedies. Innovation and Expansion IDF Establishes a Working Group to Examined New Type 5 Diabetes In April 2025, A working group to create formal diagnostic criteria and treatment guidelines for a type of diabetes associated with malnutrition that was officially designated as 'type 5 diabetes' during an international meeting of experts in India earlier this year was announced by IDF President Professor Peter Schwarz at the recent International Diabetes Federation (IDF) World Diabetes Congress 2025 in Bangkok, Thailand. Additionally, the working group will create educational modules to teach healthcare professionals and a worldwide research registry. Between 20 and 25 million individuals globally are thought to have type 5 diabetes, mostly in Asia and Africa. This discovery represents a turning point in our knowledge of diabetes and its impact on undernourished and lean adolescents and young adults in low- and middle-income (LMIC) nations. Cipla Takes Center Stage as CDSCO Authorized the Launch of Inhaled Insulin In December 2024, Following the Central Drugs Standard Control Organization's (CDSCO) approval of Cipla's exclusive distribution and marketing of Afrezza, an inhalation human insulin, in India, the company's stock will continue to be closely watched. Unlike existing insulins that are administered as injections, Afrezza is a rapid-acting insulin that is administered via inhalation. When taken at the start of a meal, Afrezza dissolves swiftly in the lungs when inhaled orally and immediately gets insulin into the circulation. Inventive Sparks, Expanding Markets Through R&D innovation, strategic alliances, and entry into developing markets, non-insulin treatment firms are propelling growth. They concentrate on creating safer, more efficient medications, utilizing digital technologies to assist patients, and obtaining authorization for more extensive therapeutic applications. The key players operating the Non-Insulin Therapies for Diabetes Market include AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
IOL News
15-05-2025
- Health
- IOL News
Understanding Type 5 Diabetes: A landmark recognition in global health
Diabetes is a chronic condition that affects how your body processes blood sugar. Image: Artem Podrez / Pexels In a landmark announcement at the International Diabetes Federation (IDF) World Diabetes Congress 2025 in Bangkok, Thailand, a new category of diabetes, Type 5 Diabetes, was formally recognised by global health experts. This classification represents a long-overdue acknowledgement of a form of diabetes that affects millions but has remained underdiagnosed and misclassified for decades. 'The recognition of Type 5 diabetes marks a historic shift in how we approach diabetes globally. This is about equity, science, and saving lives,' says Professor Peter Schwarz, President of the IDF. What is type 5 diabetes? Type 5 diabetes, also known as malnutrition-related diabetes, is a newly classified form of diabetes driven primarily by chronic undernutrition, especially during the formative years of childhood and adolescence. The condition leads to impaired development of the pancreas, resulting in severe insulin deficiency. Unlike other types of diabetes, however, this form is not caused by autoimmunity, as in Type 1, or insulin resistance, as in Type 2. Who is affected? Type 5 diabetes is estimated to impact 20–25 million people worldwide, particularly in low- and middle-income countries (LMICs) across Asia and Africa. Those affected are often teens and young adults, lean or underweight individuals and those living in resource-limited settings. Because of its unique characteristics, it has often been misclassified as either Type 1 or Type 2 diabetes in clinical settings, leading to inappropriate treatment strategies. A major focus of the new IDF Working Group on Type 5 Diabetes, led by Dr. Meredith Hawkins (Albert Einstein College of Medicine, USA) and Dr. Nihal Thomas (Christian Medical College, India), is to: Develop formal diagnostic criteria Establish a global patient registry Create educational materials for health workers in LMICs Explore cost-effective therapies Here's a breakdown of all types of diabetes Type 1 diabetes Cause: Autoimmune destruction of insulin-producing beta cells Onset: Typically in children and young adults Insulin resistance: Absent Treatment: Lifelong insulin therapy Prevalence: 5–10% of all diabetes cases Type 2 diabetes Cause: Insulin resistance and eventual insulin production decline Onset: Usually adulthood, but increasingly seen in youth Risk factors: Obesity, sedentary lifestyle, genetics Treatment: Diet, exercise, oral meds, sometimes insulin Prevalence: ~90% of all diabetes cases Gestational diabetes Cause: Hormonal changes during pregnancy leading to insulin resistance Onset: During pregnancy Risk: Increased future risk of Type 2 diabetes for both mother and child Treatment: Diet, exercise, insulin if needed Monogenic diabetes Cause: Single gene mutations affecting insulin production Onset: Often in childhood or young adulthood Treatment: Varies because some forms are responsive to sulfonylureas Type 3c diabetes Cause: Damage to the pancreas (e.g., pancreatitis, cancer, surgery) Onset: Variable, depending on pancreatic disease Treatment: Insulin and enzyme replacement Type 5 diabetes (new) Cause: Chronic malnutrition impairs pancreatic development Onset: Teens and young adults, especially in LMICs Insulin resistance: Low Treatment: Often oral medications; tailored to resource availability Prevalence: 20–25 million globally (mostly unrecognised) The recognition of Type 5 Diabetes is more than just a medical milestone, it is a step toward health equity for the millions of people in developing regions who have lacked proper diagnosis and care. The evolution of diabetes classification reflects the growing understanding that diabetes is not a one-size-fits-all disease. With Type 5 diabetes now formally recognised, global healthcare systems have an opportunity, and a responsibility, to adapt diabetes care to diverse populations and unique socioeconomic contexts. IOL Lifestyle
